Erin R. Rudzinski

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Medicine, Oncology, Pharmacology +16

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong, Steven G. DuBois, Shivaani Kummar et al. · The Lancet Oncology · 2020 · 994 citations · Full text

Medicine, Oncology, Immunotherapy +14

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

Theodore W. Laetsch, Steven G. DuBois, Leo Mascarenhas et al. · The Lancet Oncology · 2018 · 552 citations · Full text

Medicine, Molecular Biology, Oncology +16

<i>PAX-FOXO1</i> fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report

Stephen X. Skapek, James R. Anderson, Frederic G. Barr et al. · Pediatric Blood & Cancer · 2013 · 274 citations

Medicine, Oncology, Pathology +17

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium

Jack F. Shern, Joanna Selfe, Elisa Izquierdo et al. · Journal of Clinical Oncology · 2021 · 211 citations · Full text

Medicine, Genetics, Oncology +17